The Cancer Prevention and Control Program (CPCP) is a multidisciplinary effort to reduce overall and specific cancer incidence, mortality and morbidity in men and women across the age spectrum by conducting community-based interventional research. The major research areas are;1) primary prevention: identifying and implementing effective lifestyle (eg diet, exercise, weight control, smoking cessation), medical (eg chemoprevention, vaccines), and community interventions designed to prevent cancer development through dissemination and adoption of preventive strategies;2) secondary prevention;improving use of early detection programs and identifying and implementing optimal early diagnostic techniques;3) tertiary prevention: identifying and implementing effective lifestyle, medical and community interventions designed to improve the health and quality of life of persons living with or dying of cancer, and improving adherence to and effectiveness of treatments and quality of cancer care and management (eg emotional support, survivorship and quality of life of cancer patients, their families and caregivers). Cross-cutting these three areas is a focus on understanding and reducing the unequal burden of cancer in specific population groups. Plans for the next five years include: 1) tailoring current lifestyle interventions and assessment research to populations at greatest risk for specific types of cancer;2) expanding community health and health disparity research;3) enhancing intraprogrammatic collaborations among CPCP investigators to develop a cohesive research agenda;4) identifying translational opportunities and building strong inter-programmatic collaborations, particularly with investigators in Cancer Epidemiology (Program 09) and Immunology (Program 07), the latter of which may affect or be affected by the psychophysiology of cancer-related stress, and with the Shared Resources;5) strengthening the health policy research agenda for cancer prevention;and 6) enhancing and exploring current and new collaborations with cancer researchers at other institutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-05
Application #
8281620
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
5
Fiscal Year
2011
Total Cost
$13,982
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Pollom, Erqi L; Fujimoto, Dylann K; Han, Summer S et al. (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11-i18
Nørgaard, Caroline Holm; Jakobsen, Lasse Hjort; Gentles, Andrew J et al. (2018) Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One 13:e0193249
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442

Showing the most recent 10 out of 322 publications